Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of Zamicastat in Healthy Volunteers
NCT03708146Phase 1Completed
- Sponsor
- BIAL
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamicastat in pulmonary arterial hypertension (PAH) (11 cohorts), sponsored by BIAL. Primary endpoints: Maximum Observed Concentration at Day 10, Minimum Observed Concentration at Day 10 and 11 more. Started May 2018; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03708146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708146.